CJC-1295 is a research compound. It is not approved by the FDA or any regulatory body for human use. This article is for educational and informational purposes only. Nothing here constitutes medical advice. Consult a qualified physician before considering any peptide use.
The half-life of CJC-1295 is ~30 minutes (no DAC), ~8 days (with DAC). This means dosing 1-3 times daily, typically before bed is typical to maintain stable levels. The half-life directly affects how long CJC-1295 remains active and influences optimal injection timing.
What Is the Half-Life of CJC-1295?
The half-life of CJC-1295 is ~30 minutes (no DAC), ~8 days (with DAC). This is the time it takes for blood concentration to drop by 50% after administration.
Understanding half-life is essential for designing effective dosing protocols — it determines how often you need to administer CJC-1295 to maintain therapeutic blood levels.
What Does CJC-1295's Half-Life Mean for Dosing?
With a half-life of ~30 minutes (no DAC), ~8 days (with DAC), CJC-1295 requires dosing 1-3 times daily, typically before bed to maintain stable levels. The standard dosage of 100-300 mcg via subcutaneous injection accounts for this pharmacokinetic profile.
After approximately 4-5 half-lives, CJC-1295 reaches steady-state concentration — the point where the amount being absorbed equals the amount being eliminated. For CJC-1295, this occurs within the first few days of consistent dosing.
When Is the Best Time to Inject CJC-1295?
Optimal timing depends on your research goals. A half-life of ~30 minutes (no DAC), ~8 days (with DAC) means peak blood levels occur shortly after injection and decline predictably.
Common timing approaches: morning injection for daytime activity, pre-bed injection for overnight effects, or split dosing (1-3 times daily, typically before bed) for more stable levels throughout the day.
How Does CJC-1295's Half-Life Compare to Similar Peptides?
CJC-1295 is a Growth Hormone Releasing Hormone (GHRH) analog. Its half-life of ~30 minutes (no DAC), ~8 days (with DAC) positions it with a shorter duration of action compared to some alternatives in this class.
Shorter half-lives require more frequent dosing but allow for more precise control. Longer half-lives are more convenient but carry risk of accumulation.
Calculate Your CJC-1295 Dose
Use our free peptide dosing calculator to get exact reconstitution math and syringe units for CJC-1295.
Open Calculator →Bottom Line: CJC-1295 Half-Life and Dosing
CJC-1295 has a half-life of ~30 minutes (no DAC), ~8 days (with DAC), supporting the standard protocol of 100-300 mcg dosed 1-3 times daily, typically before bed over 8-12 weeks, often paired with Ipamorelin.
Read our CJC-1295 dosage guide for complete protocol details.
Complete Guide
CJC-1295 : Benefits, Dosage, Side Effects & Research
Related Reading
- CJC-1295 Dosage Guide
- CJC-1295 Benefits
- CJC-1295 Side Effects
- CJC-1295 Stacking Guide
- CJC-1295 Cycle Guide
- CJC-1295 Research
Research-Grade Sourcing
If you're going to research CJC-1295, source matters. These are the suppliers WolveStack has vetted for purity and third-party testing.
Frequently Asked Questions
What is CJC-1295?
CJC-1295 (CJC-1295 (Modified GRF 1-29)) is a Growth Hormone Releasing Hormone (GHRH) analog. Synthetic peptide analog of GHRH (first 29 amino acids) with four amino acid substitutions for enhanced stability. It is researched for increased growth hormone secretion, improved body composition, better sleep quality, enhanced recovery, anti-aging effects.
What is the recommended CJC-1295 dosage?
Common dosages: 100-300 mcg administered 1-3 times daily, typically before bed via subcutaneous injection. Cycle length: 8-12 weeks, often paired with Ipamorelin. Half-life: ~30 minutes (no DAC), ~8 days (with DAC). Use our peptide calculator for exact reconstitution math.
What are the side effects of CJC-1295?
Possible water retention, tingling/numbness in hands (carpal tunnel-like), increased appetite, mild headache, and flushing at injection site. Effects are dose-dependent and typically subside with continued use.
Is CJC-1295 safe?
CJC-1295 has shown a preliminary safety profile in research. Not FDA-approved. Research chemical status. Banned by WADA. All research should follow appropriate safety protocols.